This segment focuses on the development, commercialization, and research of therapies for Multiple Sclerosis (MS). The primary product in this segment is Ampyra (dalfampridine), an oral drug designed to improve walking ability in MS patients. Research and development activities include clinical trials and ongoing studies to assess the efficacy and safety of Ampyra. The company utilizes advanced pharmaceutical technologies for drug formulation and delivery. The impact on patients is significant, as Ampyra can improve mobility and quality of life. Acorda's market positioning is strong due to Ampyra's established presence, but faces competition from other MS treatments. Future opportunities include expanding the use of Ampyra and developing new therapies for MS. Regulatory aspects involve FDA approval and compliance with pharmaceutical regulations. Partnerships with Biogen Inc. have been crucial for the development and commercialization of Ampyra.

This segment is dedicated to the development and commercialization of therapies for Parkinson's disease, specifically focusing on treatments for OFF periods. The key product is Inbrija, an inhaled levodopa for the treatment of OFF periods in Parkinson's disease. Research and development efforts include clinical trials to evaluate the efficacy and safety of Inbrija. The company employs advanced drug delivery technologies, such as inhalation devices, to administer the medication. The impact on patients is substantial, as Inbrija helps manage motor fluctuations and improve daily functioning. Acorda's market position is focused on providing effective treatments for Parkinson's disease. Future opportunities include expanding the use of Inbrija and developing new therapies for Parkinson's disease. Regulatory aspects involve obtaining approvals from regulatory bodies. The company is focused on providing effective treatments for Parkinson's disease.

This segment encompasses the company's research and development activities, including the discovery and development of new therapies for neurological disorders. This includes the development of ARCUS product for the treatment of acute migraine, rHIgM22, which has completed Phase I clinical trial for the treatment of MS, and Cimaglermin alfa for heart failure patients. The company utilizes various technologies and methodologies, including drug discovery, clinical trials, and advanced pharmaceutical research. The therapeutic areas covered include multiple sclerosis, Parkinson's disease, and other neurological conditions. The patient impact is focused on developing innovative treatments to improve the lives of individuals with neurological disorders. Market positioning is based on innovation and the development of novel therapies. Future opportunities include expanding the pipeline of drug candidates and advancing clinical trials. Regulatory aspects involve obtaining approvals from regulatory bodies. The company collaborates with other organizations to advance its research and development efforts.